In this blog post, we take a look at the latest happenings around Parkinson’s disease.
Cancer Medicine Can Be Used to Treat Parkinson’s
Tasigna, an approved drug for leukemia, was found to boost dopamine levels in Parkinson’s patients. A Phase 2 trial conducted by Georgetown University to test the drug’s tolerability, pharmacokinetic properties, and safety showed a 20% decrease in alpha-synuclein and 30% reduction in tau - alpha-synuclein. Tau is known as a biomarker for Parkinson’s. To read more click here
Excessive Use of Oral Antibiotics May Lead To Parkinson’s
A recent study by researchers from Helsinki University Hospital suggests that increased use of oral antibiotics can predispose a person towards Parkinson's disease. The disruptive effect of the antibiotics on gut microbiota could be a leading factor. To read more click here
Parkinson’s Gets a New Vehicle for Gene Therapy Delivery
A team of Swedish researchers has developed a new gene therapy delivery method called barcoded rational AAV vector evolution (BRAVE). It is a system that uses cell-specific adeno-associated viruses for treatment of Parkinson’s disease. To read more click here
Stanford Discovers A New Therapeutic Approach
Scientists at Stanford have identified a small molecule that enables removal of a mitochondrial protein, Miro, in many Parkinson’s disease patients and helps to prevent the death of neurons. To read more click here
Strategy to Target Misfolded Alpha-synuclein in Mouse Model
A team of researchers at the University of Pennsylvania have created antibodies that target the misfolded form of alpha-synuclein protein in mice with Parkinson’s disease, thereby improving dopamine levels in mice. To read more click here
Interested to know more about the new therapeutic approaches to Parkinson’s disease? Check out our post here.
To know more about MaxVal’s Search and Analytics services, click here.